Cover Image
Market Research Report

Generics in North America

Published by MarketLine Product code 353041
Published Content info 34 Pages
Delivery time: 1-2 business days
Price
Back to Top
Generics in North America
Published: January 4, 2016 Content info: 34 Pages
Description

Generics in North America industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the North America generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

  • For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The North American generics market is expected to generate total revenues of $105.4bn in 2015, representing a compound annual growth rate (CAGR) of 6.4% between 2011 and 2015.
  • Market consumption volume is forecast to reach a total of 88.7 % of total pharma volume in 2015.
  • The North American marketed is dominated by the US, which accounts for nearly 90% of the market's revenues.

Features

  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in North America
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in North America
  • Leading company profiles reveal details of key generics market players' global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the North America generics market with five year forecasts by both value and volume
  • Macroeconomic indicators provide insight into general trends within the North America economy

Key Questions Answered

  • What was the size of the North America generics market by value in 2015?
  • What will be the size of the North America generics market in 2020?
  • What factors are affecting the strength of competition in the North America generics market?
  • How has the market performed over the last five years?
  • How large is North America's generics market in relation to its regional counterparts?
Table of Contents
Product Code: OHME5132

Table of Contents

Executive Summary

  • Market value
  • Market value forecast
  • Market volume
  • Market volume forecast
  • Geography segmentation
  • Market rivalry

Market Overview

  • Market definition
  • Market analysis

Market Data

  • Market value
  • Market volume

Market Segmentation

  • Geography segmentation

Market Outlook

  • Market value forecast
  • Market volume forecast

Five Forces Analysis

  • Summary
  • Buyer power
  • Supplier power
  • New entrants
  • Threat of substitutes
  • Degree of rivalry

Leading Companies

  • Allergan plc
  • Mylan Inc.
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Limited

Methodology

  • Industry associations
  • Related MarketLine research

Appendix

  • About MarketLine

List of Tables

  • Table 1: North America generics market value: $ billion, 2011-15(e)
  • Table 2: North America generics market volume: % of total pharma volume, 2011-15(e)
  • Table 3: North America generics market geography segmentation: $ billion, 2015(e)
  • Table 4: North America generics market value forecast: $ billion, 2015-20
  • Table 5: North America generics market volume forecast: % of total pharma volume, 2015-20
  • Table 6: Allergan plc: key facts
  • Table 7: Allergan plc: key financials ($)
  • Table 8: Allergan plc: key financial ratios
  • Table 9: Mylan Inc.: key facts
  • Table 10: Mylan Inc.: key financials ($)
  • Table 11: Mylan Inc.: key financial ratios
  • Table 12: Sandoz International GmbH: key facts
  • Table 13: Teva Pharmaceutical Industries Limited: key facts
  • Table 14: Teva Pharmaceutical Industries Limited: key financials ($)
  • Table 15: Teva Pharmaceutical Industries Limited: key financial ratios

List of Figures

  • Figure 1: North America generics market value: $ billion, 2011-15(e)
  • Figure 2: North America generics market volume: % of total pharma volume, 2011-15(e)
  • Figure 3: North America generics market geography segmentation: % share, by value, 2015(e)
  • Figure 4: North America generics market value forecast: $ billion, 2015-20
  • Figure 5: North America generics market volume forecast: % of total pharma volume, 2015-20
  • Figure 6: Forces driving competition in the generics market in North America, 2015
  • Figure 7: Drivers of buyer power in the generics market in North America, 2015
  • Figure 8: Drivers of supplier power in the generics market in North America, 2015
  • Figure 9: Factors influencing the likelihood of new entrants in the generics market in North America, 2015
  • Figure 10: Factors influencing the threat of substitutes in the generics market in North America, 2015
  • Figure 11: Drivers of degree of rivalry in the generics market in North America, 2015
  • Figure 12: Allergan plc: revenues & profitability
  • Figure 13: Allergan plc: assets & liabilities
  • Figure 14: Mylan Inc.: revenues & profitability
  • Figure 15: Mylan Inc.: assets & liabilities
  • Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability
  • Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities
Back to Top